药品管理法实施条例迎来23年来首次全面修订 如何更好满足用药需求？

Core Viewpoint - The newly revised "Regulations for the Implementation of the Drug Administration Law of the People's Republic of China" will take effect on May 15, marking the first comprehensive revision in 23 years, with over 90% of the provisions modified to better meet public medication needs [1][3]. Group 1: Regulatory Changes - The focus of the regulations has shifted from managing drug production and operation enterprises to centering on the responsibilities of drug marketing authorization holders, enhancing strict supervision throughout the entire lifecycle of drugs [3]. - Four expedited pathways for drug approval have been clearly defined in the new regulations, including breakthrough therapy drugs, conditional approvals, priority reviews, and special approvals [4]. Group 2: Intellectual Property and Market Exclusivity - The revised regulations expand the drug trial data protection system and introduce a market exclusivity period for drugs, particularly benefiting rare disease medications and pediatric drugs, with exclusivity periods of up to 7 years for rare diseases and 2 years for pediatric drugs [6][7]. - The data protection period allows innovative drug companies to achieve reasonable returns, which supports ongoing research and development, while after this period, generic drug companies can simplify their market applications using original drug data, potentially lowering drug prices [9]. Group 3: Online Drug Sales Regulation - The online retail scale of drugs in China is projected to exceed 700 billion yuan in 2024 and 800 billion yuan in 2025, prompting the need for clear regulations to ensure the quality and safety of online drug purchases [10]. - The new regulations specify the obligations of online platforms, requiring them to rigorously verify the qualifications of drug sellers and to maintain relevant management records [12]. Group 4: Traditional Chinese Medicine (TCM) Standards - The revised regulations encourage the implementation of quality management standards for the production of traditional Chinese medicine materials, aiming to standardize and enhance the development level of TCM [14].